The Chinese government has identified biotechnology as a national strategic priority in its drive for self-sufficiency. This approach is bearing fruit and challenging US influence, much like in the electric vehicle sector. World Health Organization data from November 2025 shows that the US led with 197,090 registered clinical trials, accounting for 20% of the total. However, from January 2024 to June 2025, China with 24% and India with 23% overtook the US in new studies registered. In 2024, China registered 7,100 clinical trials, while the US registered 6,000. According to other data, China registered 4,900 clinical trials in 2024, an increase of 13.9% from 2023, of which 2,539 were for innovative drugs. Oncology was the most common field, with a significant increase of 42% in cell and gene therapy studies. The Chinese company Jiangsu Hengrui Pharmaceuticals has become the largest sponsor of clinical trials in the world.